Filing Flows › Comparisons › CTOR vs CTXR
Citius Oncology vs Citius Pharmaceuticals: CTOR and CTXR compared
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Citius Pharmaceuticals (Q3 FY26). Citius Oncology is more profitable, with an operating margin of -583.5% against -785.4%.
Where the money goes: CTOR and CTXR
Citius Oncology (CTOR) · Q3 FY26
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Citius Pharmaceuticals (CTXR) · Q3 FY26
Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Citius Oncology (CTOR) | Citius Pharmaceuticals (CTXR) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 FY26 |
| Revenue | $1.5M | $1.5M |
| Operating margin | -583.5% | -785.4% |
| Net earnings | −$8.9M | −$11.9M |
| Net margin | -597.4% | -797.9% |
| Operating cash flow | −$2.7M | −$8.7M |
Questions
Which is bigger, Citius Oncology or Citius Pharmaceuticals?
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Citius Pharmaceuticals (Q3 FY26).
Is Citius Oncology or Citius Pharmaceuticals growing faster?
Citius Oncology is more profitable, with an operating margin of -583.5% against -785.4%.
More: Citius Oncology earnings · how Citius Oncology makes money · Citius Pharmaceuticals earnings · how Citius Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.